Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Sep;62(9):3994–3999. doi: 10.1128/iai.62.9.3994-3999.1994

An anti-idiotype antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge with endotoxin.

S K Field 1, D C Morrison 1
PMCID: PMC303058  PMID: 8063418

Abstract

Recently, we described the generation and characterization of an Armenian hamster Ab2 beta anti-idiotype monoclonal antibody (MAb4G2) specific for the binding site of a mouse monoclonal antibody, MAbY1-4A6, directed against the conserved 2-keto-3-deoxyoctulosonate (Kdo)-containing inner-core region of lipopolysaccharide (LPS) (S. K. Field, M. Pollack, and D. C. Morrison, Microb. Pathog. 15:103-120, 1993). In that study, mice and hamster immunized with MAb4G2 generated serum immunoglobulin G and M (IgG and IgM) antibodies which cross-react with Salmonella minnesota R595-chemotype rough mutant LPS (Re-LPS). In this report, we demonstrate that in C3Heb/FeJ mice, MAb4G2 elicits an immune response which is characterized by specific binding of antibody to Re-LPS, as assessed by enzyme-linked immunosorbent assay. The practical use of MAb4G2 as a potentially effective therapeutic agent against gram-negative bacterial sepsis is suggested by the demonstration that immunization of these mice with MAb4G2 results in significant protection of D-galactosamine-sensitized animals against an otherwise lethal dose of Re-LPS. Assessment of the temporal changes in Re-LPS-specific serum antibody titers from mice immunized with MAb4G2 or Re-LPS over a 40-day period indicates that immunization with Re-LPS elicits significantly higher titers of serum IgM antibodies compared with those in animals immunized with MAb4G2. Conversely, two immunizations with MAb4G2 result in an up to 10-fold increase in anti-Re-LPS-specific IgG serum antibody titers relative to those obtained in mice immunized with Re-LPS. Nineteen days after the secondary boost with MAb4G2, anti-Re-LPS-specific IgG serum antibody titers were significantly higher (three- to fourfold) compared with those in Re-LPS-treated animals. Initial immunization with the anti-idiotype antibody primes animals for enhanced secondary responses to Re-LPS, as assessed by the titers of anti-Re-LPS-specific IgG profiles. These data suggest the potential utility of MAb4G2 as a candidate vaccine against the lethal properties of gram-negative bacterial LPS.

Full text

PDF
3994

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumgartner J. D., Glauser M. P., McCutchan J. A., Ziegler E. J., van Melle G., Klauber M. R., Vogt M., Muehlen E., Luethy R., Chiolero R. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 1985 Jul 13;2(8446):59–63. doi: 10.1016/s0140-6736(85)90176-x. [DOI] [PubMed] [Google Scholar]
  2. Bona C. A., Heber-Katz E., Paul W. E. Idiotype-anti-idiotype regulation. I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones. J Exp Med. 1981 Apr 1;153(4):951–967. doi: 10.1084/jem.153.4.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bona C., Moran T. Idiotype vaccines. Ann Inst Pasteur Immunol. 1985 May-Jun;136C(3):299–312. doi: 10.1016/s0769-2625(85)80002-7. [DOI] [PubMed] [Google Scholar]
  4. Braude A. I., Douglas H. Passive immunization against the local Shwartzman reaction. J Immunol. 1972 Feb;108(2):505–512. [PubMed] [Google Scholar]
  5. Braude A. I., Ziegler E. J., Douglas H., McCutchan J. A. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. J Infect Dis. 1977 Aug;136 (Suppl):S167–S173. doi: 10.1093/infdis/136.supplement.s167. [DOI] [PubMed] [Google Scholar]
  6. Calandra T., Cometta A. Antibiotic therapy for gram-negative bacteremia. Infect Dis Clin North Am. 1991 Dec;5(4):817–834. [PubMed] [Google Scholar]
  7. Centers for Disease Control (CDC) Increase in National Hospital Discharge Survey rates for septicemia--United States, 1979-1987. MMWR Morb Mortal Wkly Rep. 1990 Jan 19;39(2):31–34. [PubMed] [Google Scholar]
  8. Davis C. E., Ziegler E. J., Arnold K. F. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J Exp Med. 1978 Apr 1;147(4):1007–1017. doi: 10.1084/jem.147.4.1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dreesman G. R., Kennedy R. C. Anti-idiotypic antibodies: implications of internal image-based vaccines for infectious diseases. J Infect Dis. 1985 May;151(5):761–765. doi: 10.1093/infdis/151.5.761. [DOI] [PubMed] [Google Scholar]
  10. Field S., Pollack M., Morrison D. C. Development of an anti-idiotype monoclonal antibody mimicking the structure of lipopolysaccharide (LPS) inner-core determinants. Microb Pathog. 1993 Aug;15(2):103–120. doi: 10.1006/mpat.1993.1061. [DOI] [PubMed] [Google Scholar]
  11. Freudenberg M. A., Galanos C. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun. 1988 May;56(5):1352–1357. doi: 10.1128/iai.56.5.1352-1357.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Galanos C., Freudenberg M. A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5939–5943. doi: 10.1073/pnas.76.11.5939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gaulton G. N., Sharpe A. H., Chang D. W., Fields B. N., Greene M. I. Syngeneic monoclonal internal image anti-idiotopes as prophylactic vaccines. J Immunol. 1986 Nov 1;137(9):2930–2936. [PubMed] [Google Scholar]
  14. Greenman R. L., Schein R. M., Martin M. A., Wenzel R. P., MacIntyre N. R., Emmanuel G., Chmel H., Kohler R. B., McCarthy M., Plouffe J. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991 Aug 28;266(8):1097–1102. [PubMed] [Google Scholar]
  15. Hiernaux J., Bona C., Baker P. J. Neonatal treatment with low doses of anti-idiotypic antibody leads to the expression of a silent clone. J Exp Med. 1981 Apr 1;153(4):1004–1008. doi: 10.1084/jem.153.4.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jacobs D. M., Morrison D. C. Stimulation of a T-independent primary anti-hapten response in vitro by TNP-lipopolysaccharide (TNP-LPS). J Immunol. 1975 Jan;114(1 Pt 2):360–364. [PubMed] [Google Scholar]
  17. Jerne N. K., Roland J., Cazenave P. A. Recurrent idiotopes and internal images. EMBO J. 1982;1(2):243–247. doi: 10.1002/j.1460-2075.1982.tb01154.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jerne N. K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974 Jan;125C(1-2):373–389. [PubMed] [Google Scholar]
  19. Johns M., Skehill A., McCabe W. R. Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin. J Infect Dis. 1983 Jan;147(1):57–67. doi: 10.1093/infdis/147.1.57. [DOI] [PubMed] [Google Scholar]
  20. Kato T., Takazoe I., Okuda K. Protection of mice against the lethal toxicity of a lipopolysaccharide (LPS) by immunization with anti-idiotype antibody to a monoclonal antibody to lipid A from Eikenella corrodens LPS. Infect Immun. 1990 Feb;58(2):416–420. doi: 10.1128/iai.58.2.416-420.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kennedy R. C., Dreesman G. R. Enhancement of the immune response to hepatitis B surface antigen. In vivo administration of antiidiotype induces anti-HBs that expresses a similar idiotype. J Exp Med. 1984 Mar 1;159(3):655–665. doi: 10.1084/jem.159.3.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kieber-Emmons T., Ward R. E., Raychaudhuri S., Rein R., Kohler H. Rational design and application of idiotope vaccines. Int Rev Immunol. 1986 Jan;1(1):1–26. doi: 10.3109/08830188609056598. [DOI] [PubMed] [Google Scholar]
  23. Käyhty H., Karanko V., Peltola H., Mäkelä P. H. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics. 1984 Nov;74(5):857–865. [PubMed] [Google Scholar]
  24. McCabe W. R. Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol. 1972 Mar;108(3):601–610. [PubMed] [Google Scholar]
  25. McNamara M. K., Ward R. E., Kohler H. Monoclonal idiotope vaccine against Streptococcus pneumoniae infection. Science. 1984 Dec 14;226(4680):1325–1326. doi: 10.1126/science.6505692. [DOI] [PubMed] [Google Scholar]
  26. Morrison D. C., Ryan J. L. Bacterial endotoxins and host immune responses. Adv Immunol. 1979;28:293–450. doi: 10.1016/s0065-2776(08)60802-0. [DOI] [PubMed] [Google Scholar]
  27. Morrison D. C., Silverstein R., Bright S. W., Chen T. Y., Flebbe L. M., Lei M. G. Monoclonal antibody to mouse lipopolysaccharide receptor protects mice against the lethal effects of endotoxin. J Infect Dis. 1990 Nov;162(5):1063–1068. doi: 10.1093/infdis/162.5.1063. [DOI] [PubMed] [Google Scholar]
  28. Morrison D. C., Ulevitch R. J. The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol. 1978 Nov;93(2):526–618. [PMC free article] [PubMed] [Google Scholar]
  29. Mosier D. E., Zaldivar N. M., Goldings E., Mond J., Scher I., Paul W. E. Formation of antibody in the newborn mouse: study of T-cell-independent antibody response. J Infect Dis. 1977 Aug;136 (Suppl):S14–S19. doi: 10.1093/infdis/136.supplement.s14. [DOI] [PubMed] [Google Scholar]
  30. Nisonoff A. Idiotypes: concepts and applications. J Immunol. 1991 Oct 15;147(8):2429–2438. [PubMed] [Google Scholar]
  31. Nisonoff A., Lamoyi E. Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production. Clin Immunol Immunopathol. 1981 Dec;21(3):397–406. doi: 10.1016/0090-1229(81)90228-2. [DOI] [PubMed] [Google Scholar]
  32. Pollack M., Chia J. K., Koles N. L., Miller M., Guelde G. Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J Infect Dis. 1989 Feb;159(2):168–188. doi: 10.1093/infdis/159.2.168. [DOI] [PubMed] [Google Scholar]
  33. Roitt I. M., Cooke A., Male D. K., Hay F. C., Guarnotta G., Lydyard P. M., de Carvalho L. P., Thanavala Y., Ivanyi J. Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet. 1981 May 9;1(8228):1041–1045. doi: 10.1016/s0140-6736(81)92199-1. [DOI] [PubMed] [Google Scholar]
  34. Slack J., Der-Balian G. P., Nahm M., Davie J. M. Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J Exp Med. 1980 Apr 1;151(4):853–862. doi: 10.1084/jem.151.4.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Stein K. E., Söderström T. Neonatal administration of idiotype or antiidiotype primes for protection against Escherichia coli K13 infection in mice. J Exp Med. 1984 Oct 1;160(4):1001–1011. doi: 10.1084/jem.160.4.1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Su S., Ward M. M., Apicella M. A., Ward R. E. A nontoxic, idiotope vaccine against gram-negative bacterial infections. J Immunol. 1992 Jan 1;148(1):234–238. [PubMed] [Google Scholar]
  37. Warren H. S., Danner R. L., Munford R. S. Anti-endotoxin monoclonal antibodies. N Engl J Med. 1992 Apr 23;326(17):1153–1157. doi: 10.1056/NEJM199204233261711. [DOI] [PubMed] [Google Scholar]
  38. Westerink M. A., Campagnari A. A., Wirth M. A., Apicella M. A. Development and characterization of an anti-idiotype antibody to the capsular polysaccharide of Neisseria meningitidis serogroup C. Infect Immun. 1988 May;56(5):1120–1127. doi: 10.1128/iai.56.5.1120-1127.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ziegler E. J., Douglas H., Sherman J. E., Davis C. E., Braude A. I. Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant. J Immunol. 1973 Aug;111(2):433–438. [PubMed] [Google Scholar]
  40. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  41. Ziegler E. J., McCutchan J. A., Fierer J., Glauser M. P., Sadoff J. C., Douglas H., Braude A. I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982 Nov 11;307(20):1225–1230. doi: 10.1056/NEJM198211113072001. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES